For patients with KRAS WT cancer across all treatment types in the 2L setting, significantly shorter OS was observed in patients with mSTK11-mKEAP1 vs STK11 WT-KEAP1 WT (3.5 vs 8.3 months; aHR, 1.83; 95% CI, 1.35–2.49; p < 0.001) (Fig. 4C). Here, KRAS is linked to cancer.